A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced initial burst effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use.

A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced initial burst effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use.

A solvent-removing apparatus according to an embodiment includes a tank body accommodating an emulsion including first source material in a continuous phase and second source material in a dispersed phase, a fluid supply unit for supplying fluid into the tank body to cause the emulsion to circulate, and a discharge unit for discharging the gas in the tank body to the outside.

A process of manufacturing a polyester from cyclic ester monomer comprises the steps of: a) providing a cyclic ester, b) polymerizing the cyclic ester in the presence of a catalyst and optionally an initiator in a reactor to form a reaction mixture comprising polyester and unreacted cyclic ester, wherein after the polymerization at least one polymerization inhibitor is added to the reaction mixture, wherein the polymerization inhibitor is selected from the group consisting of monoimines, diimines, mono alkyl phosphates according to the formula RPO.sub.4H.sub.2, wherein R is a C.sub.6-16 linear, branched or cyclic alkyl group, di alkyl phosphates according to the formula R.sub.2PO.sub.4H, wherein each R is independently a C.sub.6-16 linear, branched or cyclic alkyl group or a combination thereof, and phosphate esters according to the general formula (I) wherein at least one of R, R and R has the general structure as in general formula (II) wherein n>0 and Q is independently a C.sub.1-16 linear, branched or substituted alkyl group, and R is independently an H or linear, branched, cyclic or substituted alkyl group or a phenyl group derivative, and wherein any of R, R and R not having the general structure as in general formula (II) is independently an H or a linear, branched, cyclic or substituted alkyl group or a phenyl group derivative.

A process of manufacturing a polyester from cyclic ester monomer comprises the steps of: a) providing a cyclic ester, b) polymerizing the cyclic ester in the presence of a catalyst and optionally an initiator in a reactor to form a reaction mixture comprising polyester and unreacted cyclic ester, wherein after the polymerization at least one polymerization inhibitor is added to the reaction mixture, wherein the polymerization inhibitor is selected from the group consisting of monoimines, diimines, mono alkyl phosphates according to the formula RPO.sub.4H.sub.2, wherein R is a C.sub.6-16 linear, branched or cyclic alkyl group, di alkyl phosphates according to the formula R.sub.2PO.sub.4H, wherein each R is independently a C.sub.6-16 linear, branched or cyclic alkyl group or a combination thereof, and phosphate esters according to the general formula (I) wherein at least one of R, R and R has the general structure as in general formula (II) wherein n>0 and Q is independently a C.sub.1-16 linear, branched or substituted alkyl group, and R is independently an H or linear, branched, cyclic or substituted alkyl group or a phenyl group derivative, and wherein any of R, R and R not having the general structure as in general formula (II) is independently an H or a linear, branched, cyclic or substituted alkyl group or a phenyl group derivative.

A method for stabilizing a condensed phase composition in a process of manufacturing a polyester from cyclic ester monomer comprising the steps of devolatilizing a reaction mixture, which contains i) at least one polymerizable cyclic ester, ii) at least one catalyst and optionally at least one initiator, to produce a vapor stream and a molten residue, wherein the vapor stream includes mainly i) the at least one polymerizable cyclic ester and ii) the at least one catalyst and/or the at least one initiator and/or a reaction product or a residue of the at least one catalyst and/or the at least one initiator and condensing the vapor stream to form the condensed phase composition, wherein at least one polymerization inhibitor is added as stabilizer to the reaction mixture and/or to the condensed phase composition in an amount so that the degree of conversion of the polymerizable cyclic ester in the condensed phase composition is not more than 15%, wherein the degree of conversion is 100.square-solid.(c0C.sub.F)/c.sub.0, wherein c.sub.0 is the initial concentration of the cyclic ester in the condensed phase composition obtained by the condensation of the vapor stream and C.sub.F is the concentration of the cyclic ester in the condensed phase composition after addition of 150 ppm of tin octoate as catalyst and of 100 mmol/kg of ethyl-hexanol as initiator to the condensed phase composition and a subsequent heat treatment of condensed phase composition under inert atmosphere conditions for 12 hours at 160 C.

The present invention relates to a method for preparing polylactic acid. According to the method for preparing polylactic acid, high quality polylactic acid can be provided by effectively removing residual monomers while minimizing property changes of the polylactic acid.

The present invention relates to a method for preparing polylactic acid. According to the method for preparing polylactic acid, high quality polylactic acid can be provided by effectively removing residual monomers while minimizing property changes of the polylactic acid.

The present invention relates to a composition comprising particles, wherein said particles comprise Poly(lactide-co-glycolide) polymer, therapeutically effective amount of liraglutide or a pharmaceutically acceptable salt thereof and a hydrophilic particle size modulating agent, wherein, the composition is free of added divalent metal ions. The composition provides effective blood glucose control for about 7 days when administered as once a week formulation to a period of about 30 days after single administration of a monthly dose to a patient in need thereof.

It relates to the field of synthetic macromolecular chemistry, and discloses a method for one-step synthesis of thiol-functionalized polyester polyols by organic catalysis. This method uses lactone monomer as reaction raw material, thiol-alcohol as initiator, and diphenyl phosphate as organic catalyst to catalyze and synthesize the thiol-functionalized polyester polyols. The present invention provides a method which is simple, inexpensive, easily controllable and environmentally friendly to prepare thiol-functionalized polyester polyols with the easily available and controllable catalyst. The method can selectively catalyze the ring opening polymerization of lactone to prepare thiol-functionalized polyester polyols using the organic catalyst.